Vor Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNAT URES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| VOR BIOPHARMA INC. | ||
| Date: March 20, 2024 | By: | /s/ Robert Ang |
|---|---|---|
| Robert Ang, M.B.B.S., M.B.A. | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Robert Ang | President, Chief Executive Officer and Director (Principal Executive Officer) | March 20, 2024 |
| Robert Ang, M.B.B.S., M.B.A. | ||
| /s/ Nathan Jorgensen | Chief Financial Officer (Principal Financial Officerand Principal Accounting Officer) | March 20, 2024 |
| Nathan Jorgensen, Ph.D., M.B.A. | ||
| /s/ Matthew Patterson | Chairman of the Board | March 20, 2024 |
| Matthew Patterson | ||
| /s/ Daniella Beckman | Director | March 20, 2024 |
| Daniella Beckman | ||
| /s/ David C. Lubner | Director | March 20, 2024 |
| David C. Lubner | ||
| /s/ Sven (Bill) Ante Lundberg | Director | March 20, 2024 |
| Sven (Bill) Ante Lundberg, M.D. | ||
| /s/ Joshua Resnick | Director | March 20, 2024 |
| Joshua Resnick, M.D. | ||
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-1 |
|---|---|
| Consolidated Balance Sheets | F-2 |
| Consolidated Statements of Operations and Comprehensive Loss | F-3 |
| Consolidated Statements of Stockholders’ Equity | F-4 |
| Consolidated Statements of Cash Flows | F-5 |
| Notes to Consolidated Financial Statements | F-6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.